Galapagos (GLPG) Competitors $27.12 +0.21 (+0.78%) (As of 12/17/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends GLPG vs. LNTH, LEGN, NUVL, BPMC, ELAN, CYTK, TGTX, VKTX, BBIO, and CRNXShould you be buying Galapagos stock or one of its competitors? The main competitors of Galapagos include Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Blueprint Medicines (BPMC), Elanco Animal Health (ELAN), Cytokinetics (CYTK), TG Therapeutics (TGTX), Viking Therapeutics (VKTX), BridgeBio Pharma (BBIO), and Crinetics Pharmaceuticals (CRNX). These companies are all part of the "pharmaceutical products" industry. Galapagos vs. Lantheus Legend Biotech Nuvalent Blueprint Medicines Elanco Animal Health Cytokinetics TG Therapeutics Viking Therapeutics BridgeBio Pharma Crinetics Pharmaceuticals Lantheus (NASDAQ:LNTH) and Galapagos (NASDAQ:GLPG) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations. Do analysts prefer LNTH or GLPG? Lantheus presently has a consensus price target of $130.00, indicating a potential upside of 40.30%. Galapagos has a consensus price target of $30.75, indicating a potential upside of 13.38%. Given Lantheus' stronger consensus rating and higher probable upside, analysts plainly believe Lantheus is more favorable than Galapagos.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Galapagos 2 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.71 Does the media favor LNTH or GLPG? In the previous week, Galapagos had 5 more articles in the media than Lantheus. MarketBeat recorded 9 mentions for Galapagos and 4 mentions for Lantheus. Lantheus' average media sentiment score of 1.65 beat Galapagos' score of 0.56 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Galapagos 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer LNTH or GLPG? Galapagos received 128 more outperform votes than Lantheus when rated by MarketBeat users. However, 65.76% of users gave Lantheus an outperform vote while only 64.10% of users gave Galapagos an outperform vote. CompanyUnderperformOutperformLantheusOutperform Votes33865.76% Underperform Votes17634.24% GalapagosOutperform Votes46664.10% Underperform Votes26135.90% Do institutionals and insiders hold more shares of LNTH or GLPG? 99.1% of Lantheus shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 1.5% of Lantheus shares are owned by insiders. Comparatively, 2.9% of Galapagos shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is LNTH or GLPG more profitable? Lantheus has a net margin of 28.57% compared to Galapagos' net margin of 0.00%. Lantheus' return on equity of 44.29% beat Galapagos' return on equity.Company Net Margins Return on Equity Return on Assets Lantheus28.57% 44.29% 23.52% Galapagos N/A N/A N/A Which has higher valuation and earnings, LNTH or GLPG? Lantheus has higher revenue and earnings than Galapagos. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.50B4.30$326.66M$6.0115.42Galapagos$260.09M6.87$229.12MN/AN/A Which has more risk and volatility, LNTH or GLPG? Lantheus has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500. SummaryLantheus beats Galapagos on 12 of the 16 factors compared between the two stocks. Ad Brownstone ResearchDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.I urge you to watch this video now. Get Galapagos News Delivered to You Automatically Sign up to receive the latest news and ratings for GLPG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLPG vs. The Competition Export to ExcelMetricGalapagosPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.79B$6.87B$5.18B$9.31BDividend YieldN/A3.06%4.78%4.06%P/E RatioN/A10.80127.8817.55Price / Sales6.87286.451,262.65139.48Price / Cash41.9356.6541.1037.95Price / Book0.595.394.894.92Net Income$229.12M$152.04M$119.61M$225.78M7 Day Performance-0.33%-5.54%14.55%-1.47%1 Month Performance1.19%0.33%17.43%5.36%1 Year Performance-31.60%16.04%35.33%22.71% Galapagos Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLPGGalapagos0.74 of 5 stars$27.12+0.8%$30.75+13.4%-31.6%$1.79B$260.09M0.001,123LNTHLantheus4.4014 of 5 stars$94.27+1.3%$130.00+37.9%+21.9%$6.55B$1.50B15.42834Positive NewsLEGNLegend Biotech1.6722 of 5 stars$33.83-3.7%$81.54+141.0%-43.4%$6.18B$520.18M-36.971,800NUVLNuvalent2.3399 of 5 stars$86.65-0.2%$112.60+29.9%+9.7%$6.16BN/A-25.0340Positive NewsBPMCBlueprint Medicines2.9172 of 5 stars$95.39+2.4%$122.11+28.0%+9.7%$6.06B$249.38M-44.17640Insider TradeShort Interest ↑ELANElanco Animal Health4.2802 of 5 stars$12.09-0.1%$16.75+38.5%-10.5%$5.98B$4.45B30.259,300CYTKCytokinetics3.9849 of 5 stars$49.17+1.1%$83.93+70.7%+32.5%$5.80B$3.22M-9.04250TGTXTG Therapeutics3.8084 of 5 stars$34.78+8.6%$40.67+16.9%+81.7%$5.41B$233.66M-320.17290Positive NewsVKTXViking Therapeutics4.2772 of 5 stars$48.07+2.2%$106.75+122.1%+147.1%$5.36BN/A-51.5620BBIOBridgeBio Pharma4.7325 of 5 stars$27.86+1.3%$47.69+71.2%-29.3%$5.27B$217.77M-11.63400Analyst ForecastCRNXCrinetics Pharmaceuticals4.2142 of 5 stars$54.10+0.8%$70.82+30.9%+60.7%$5.02B$1.04M-14.39210Analyst ForecastShort Interest ↓Positive News Related Companies and Tools Related Companies LNTH Competitors LEGN Competitors NUVL Competitors BPMC Competitors ELAN Competitors CYTK Competitors TGTX Competitors VKTX Competitors BBIO Competitors CRNX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GLPG) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galapagos NV Please log in to your account or sign up in order to add this asset to your watchlist. Share Galapagos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
